Provided by Tiger Trade Technology Pte. Ltd.

Heron Therapeutics

0.8588
-0.0124-1.42%
Post-market: 0.8501-0.0087-1.01%19:43 EDT
Volume:1.05M
Turnover:912.56K
Market Cap:162.31M
PE:-4.88
High:0.8953
Open:0.8800
Low:0.8543
Close:0.8712
52wk High:2.30
52wk Low:0.7362
Shares:189.00M
Float Shares:134.00M
Volume Ratio:0.55
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1761
EPS(LYR):-0.1211
ROE:-2408.88%
ROA:-2.71%
PB:20.07
PE(LYR):-7.09

Loading ...

Analysts’ Top Healthcare Picks: Heron Therapeutics (HRTX), Viridian Therapeutics (VRDN)

TIPRANKS
·
Feb 27

Heron Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 26

Heron posts FY 2025 APONVIE net revenue USD 11.6 million up 2.6x

Reuters
·
Feb 26

Heron Therapeutics Q4 EPS $(0.02), Inline, Sales $40.588M Beat $39.533M Estimate

Benzinga
·
Feb 26

Heron Therapeutics Inc - Issues 2026 Revenue Guidance of $173-$183 Mln

THOMSON REUTERS
·
Feb 26

Heron Therapeutics Inc - Achieves $154.9 Mln in 2025 Net Revenue

THOMSON REUTERS
·
Feb 26

Heron Therapeutics Q4 Net Product Sales USD 40.588 Million

THOMSON REUTERS
·
Feb 26

Heron Therapeutics Inc expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
Feb 24

Heron Therapeutics Inc. to Report Q4 and Full Year 2025 Results

Reuters
·
Feb 17

Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum

TIPRANKS
·
Jan 10

Heron Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 10

Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target

TIPRANKS
·
Jan 10

BRIEF-Heron Therapeutics Announces Preliminary, Unaudited Q4 Results

Reuters
·
Jan 09

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

TIPRANKS
·
Jan 09

Heron Therapeutics Reports Preliminary Q4 2025 Net Revenue of $40.5 Million

Reuters
·
Jan 09

Heron Therapeutics Inc - Reports Q4 2025 Net Revenue of $40.5 Mln

THOMSON REUTERS
·
Jan 09

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; Zynrelef® Largest Contributor to Q4 Growth

THOMSON REUTERS
·
Jan 09

BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)

Reuters
·
Dec 04, 2025

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

GlobeNewswire
·
Dec 04, 2025